ReviewClinical kidney journal2020
Recurrence of immunoglobulin A nephropathy after kidney transplantation: a narrative review of the incidence, risk factors, pathophysiology and management of immunosuppressive therapy.
Review in Clinical kidney journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association of Immune and Inflammatory Gene Polymorphism With the Risk of IgA Nephropathy: A Systematic Review and Meta-Analysis of 45 Studies.Frontiers in immunology · 2021Pooled it
- Telitacicept in Recurrent IgA Nephropathy After Kidney Transplantation: Encouraging Signal, Cautious Interpretation.Kidney international reports · 2026Article
- A Prospective Pilot Study to Investigate Whether Donor-Derived Cell-Free DNA Can Be Used as a Biomarker of Recurrent IgA Nephropathy Post-Kidney Transplantation.International journal of immunogenetics · 2025Article
- Treatment of Recurrent IgA Nephropathy After Kidney Transplantation: Case Report and Comprehensive Literature Review.Clinical case reports · 2025Article
- Telitacicept treatment for recurrent IgA nephropathy after kidney transplantation.Clinical kidney journal · 2025Article
- Treating IgA Nephropathy: Looking at the Future Without Forgetting the Past.Journal of clinical medicine · 2025Review
- Longitudinal non-targeted metabolomic profiling of urine samples for monitoring of kidney transplantation patients.Renal failure · 2024Article
- Advancements in understanding the role of intestinal dysbacteriosis mediated mucosal immunity in IgA nephropathy.BMC nephrology · 2024Review
- Biologics and Non-Biologics Immunosuppressive Treatments for IgA Nephropathy in Both Adults and Children.Journal of clinical medicine · 2024Review
- C4d, rather than C3d and C5b-9, Is Associated with Graft Loss in Recurrent IgA Deposition after Kidney Transplantation.American journal of nephrology · 2024Article
- A novel prognostic nomogram predicts premature failure of kidney allografts with IgA nephropathy recurrence.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023Article
- Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy.Nature genetics · 2023Article
- Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with Immunoglobulin A Nephropathy (IgAN) in the United States.ClinicoEconomics and outcomes research : CEOR · 2023Article
- Current status of glucocorticoid usage in solid organ transplantation.World journal of transplantation · 2021Review
- Clinical outcomes and temporal trends of immunological and non-immunological rare diseases in adult kidney transplant.BMC nephrology · 2021Article
- The Pathogenesis of End-Stage Renal Disease from the Standpoint of the Theory of General Pathological Processes of Inflammation.International journal of molecular sciences · 2021Review
- Comparative Long-Term Renal Allograft Outcomes of Recurrent Immunoglobulin A with Severe Activity in Kidney Transplant Recipients with and without Rituximab: An Observational Cohort Study.Journal of clinical medicine · 2021Article
- Commentary: The Digital Fate of Glomeruli in Renal Biopsy.Journal of pathology informatics · 2021Article
- Healthcare of patients with immunoglobulin A nephropathy through a retrospective observational study of Italian administrative data.Global & regional health technology assessmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glomerulonephritis (GN) is the underlying cause of end-stage renal failure in 30-50% of kidney transplant recipients. It represents the primary cause of end-stage renal disease for 25% of the dialysis population and 45% of the transplant population. For patients with GN requiring renal replacement therapy, kidney transplantation is associated with superior outcomes compared with dialysis. Recurrent GN was previously considered to be a minor contributor to graft loss, but with the prolongation of graft survival, the effect of recurrent disease on graft outcome assumes increasing importance. Thus the extent of recurrence of original kidney disease after kidney transplantation has been underestimated for several reasons. This review aims to provide updated knowledge on one particular recurrent renal disease after kidney transplantation, immunoglobulin A nephropathy (IgAN). IgAN is one of the most common GNs worldwide. The pathogenesis of IgAN is complex and remains incompletely understood. Evidence to date is most supportive of a several hit hypothesis. Biopsy is mandatory not only to diagnose the disease in the native kidney, but also to identify and characterize graft recurrence of IgAN in the kidney graft. The optimal therapy for IgAN recurrence in the renal graft is unknown. Supportive therapy aiming to reduce proteinuria and control hypertension is the mainstream, with corticosteroids and immunosuppressive treatment tailored for certain subgroups of patients experiencing a rapidly progressive course of the disease with active lesions on renal biopsy and considering safety issues related to infectious complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.